HajarizadehB,GrebelyJ,DoreGJ, 2013.Epidemiology and natural history of HCV infection,Nat Rev Gastroenterol Hepatol 10 553 -62
LavanchyD., 2009.The global burden of hepatitis C,Liver Int 29 74 -81
2015.-vs-hepatitisC_testing,Accessed August 14 -
SeeffLB, 2002.Natural history of chronic hepatitis C,Hepatology 36 S35 -46
HamidS,UmarM,AlamA,SiddiquiA,QureshiH,ButtJ. PSG, 2004.consensus statement on management of hepatitis C virus Infection - 2003,J Pak Med Assoc 54 146 -50
PockrosPJ, 2012.Interferon-free hepatitis C therapy: how close are we?,Drugs 72 1825 -31
MannsMP,McHutchisonJG,GordonSC,RustgiVK,ShiffmanM,ReindollarR, 2001.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial,Lancet 358 958 -65
McHutchisonJG,GordonSC,SchiffER,ShiffmanML,LeeWM,RustgiVK, 1998.Interferon alfa-2b alone or in combination with Ribavirin as initial treatment for chronic hepatitis C,N Engl J Med 339 1485 -92
McHutchisonJG,LawitzEJ,ShiffmanML,MuirAJ,GallerGW,McConeJ, 2009.Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection,N Engl J Med 361 580 -93
PoordadF,McConeJ,BaconBR,BrunoS,MannsMP,SulkowskiMS, 2011.Boceprevir for untreated chronic HCV genotype 1 infection,N Engl J Med 364 1195 -206
JacobsonIM,McHutchisonJG,DusheikoG,Di BisceglieAM,ReddyKR,BzowejNH, 2011.Telaprevir for previously untreated chronic hepatitis C virus infection,N Engl J Med 364 2405 -16
2013.,Soldavi US prescribing information -
2013.,Olysio US. prescribing information -
LawitzE,MangiaA,WylesD,Rodriguez-TorresM,HassaneinT,GordonSC, 2013.Sofosbuvir for previously untreated chronic hepatitis C infection,N Engl J Med 368 1878 -87
AASLD-IDSA, 2016.Recommendations for testing, managing,(August 30 -
2015.EASL clinical practice guidelines: Management of hepatitis C virus infection,J Hepatol 63 199 -236
GaneEJ,StedmanCA,HylandRH,DingX,SvarovskaiaE,SymondsWT, 2013.Nucleotide polymerase inhibitor Sofosbuvir plus Ribavirin for hepatitis C,N Engl J Med 368 34 -44
OsinusiA,MeissnerEG,LeeYJ,BonD,HeytensL,NelsonA, 2013.Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: A randomized clinical trial,JAMA 310 804 -11
GaneEJ,StedmanCA,HylandRH,DingX,SvarovskaiaE,SymondsWT, 2013.Nucleotide polymerase inhibitor Sofosbuvir plus Ribavirin for hepatitis C,N Engl J Med 368 34 -44
JacobsonIM,GordonSC,KowdleyKV,YoshidaEM,Rodriguez-TorresM,SulkowskiMS, 2013.POSITRON study; FUSION study. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options,N Engl J Med 368 1867 -77
AkhterTS,UmarM,UmarS,NisarG,KhaarHTB,ShehzadA, 2016.Trends of Sofosbuvir treatment for chronic hepatitis C infection in genotype 3 patients: An experience from center for liver and digestive diseases,Pakistan [DDW abstract Su1461] Gastroenterology 150 S1106 -
AfdhalN,ZeuzemS,KwoP,ChojkierM,GitlinN,PuotiM, 2014.Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection,N Engl J Med 370 1889 -98
AfdhalN,ReddyKR,NelsonDR,LawitzE,GordonSC,SchiffE, 2014.Ledipasvir and Sofosbuvir for previously treated HCV genotype 1 infection,N Engl J Med 370 1483 -93
LawitzE,PoordadFF,PangPS,HylandRH,DingX,MoH, .Sofosbuvir and Ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection, -
GaneEJ,StedmanCA,HylandRH,PangPS,DingX,SymondsWT, 2013.All-oral Sofosbuvir-based 12-week regimens for the treatment of chronic HCV infection: The ELECTRON study,J Hepatol 58 S6 -S7
GuedjJ,DahariH,RongL,SansoneND,NettlesRE,CotlerSJ, 2013.Modeling shows that NS5A inhibitor Daclatasvir has two modes of action and yields a shorter estimate of hepatitis C virus half life,Proc Natl Acad Sci USA 110 3991 -6
SulkowskiMS,GardinerDF,Rodriguez-TorresM,ReddyKR,HassaneinT,JacobsonI, 2014.Daclatasvir plus Sofosbuvir for previously treated or untreated chronic HCV infection,N Engl J Med 370 211 -21
ChayamaK,SuzukiY,Ikeda K, .All-oral combination of Daclatasvir plus Asunaprevir in interferon-ineligible naive/ intolerant and non-responder Japanese patients chronically infected with HCV genotype 1b: Results from a phase 3 trial. Presented at: The 64th annual meeting of the American Association for the study of liver diseases; November 1-5, -
JacobsonI,DoreGJ,FosterGR,FriedMW,RaduM,RafalskiyVV, 2013.Simeprevir (TMC435) with peginterferon/ribavirin for chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-1, a phase III trial,J Hepatol 58 S574 -
LawitzE,FornsX,ZeuzemS,GaneE,BronowickiJP,AndreoneP, 2014.Simeprevir (TMC435) with Peginterferon/ Ribavirin for treatment of chronic HCV genotype 1 infection in patients who relapsed after previous interferon-based therapy: Results from PROMISE, a phase III trial,Gastroenterology 146 1669 -79
ZeuzemS,BergT,GaneE,FerenciP,FosterGR,FriedMW, 2014.Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: A phase IIb trial,Gastroenterology 146 430 -41
JacobsonIM,GhalibR,Rodriguez-TorresM., .SVR results of a once-daily regimen of Simeprevir (SMV, TMC435) plus Sofosbuvir (SOF, GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naïve and prior null responder patients: The COSMOS study . 2013 The Liver Meeting, -
PoordadF,SchiffER,VierlingJM, 2015.Ribavirin combination for HCV patients with advanced cirrhosis or posttranspfflt recurrence: Phase 3 ALLY-1 study [EASL abstract LO8],J Hepatol 62 S261 -62
KowdleyKV,LawitzE,PoordadF,CohenDE,NelsonDR,ZeuzemS, 2014.Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1,N Engl J Med 370 222 -32
SAPPHIRE-I-,Hepatitis-C-Patients-,- International-, 2015.-SAPPHIRE-IIStudies-in-Chronic-,Accessed August 14 -
FeldJJ,KowdleyKV,CoakleyE,SigalS,NelsonDR,CrawfordD, 2014.Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin,N Engl J Med 370 1594 -1603
ZeuzemS,JacobsonIM,BaykalT,MarinhoRT,PoordadF,BourlièreM, 2014.Retreatment of HCV with ABT-450/rombitasvir and dasabuvir with ribavirin,N Engl J Med 370 1604 -14
FerenciP,BernsteinD,LalezariJ,CohenD,LuoY,CooperC, 2014.Dasabuvir with or without ribavirin for HCV,N Engl J Med 370 1983 -92
LawitzE,GaneE,PearlmanB,TamE, 2015.Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): A randomised, openlabel phase 2 trial,Lancet -
SulkowskiM,HezodeC,GerstoftJ, 2015.Efficacy and safety of 8 weeks versus 12 weeks of treatment with Grazoprevir (MK5172) and Elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): A randomised, open-label phase 2 trial,Lancet -
2016.FDA approves Zepatier for treatment of chronic hepatitis C genotypes 1 and 4, -
FeldJJ,JacobsonIM,HézodeC,AsselahT,RuanePJ,GruenerN, 2015.,New Eng J Med 373 2599 -607
FosterGR,AfdhalN,RobertsSK,BräuN,GaneEJ,PiankoS, 2015.Sofosbuvir and Velpatasvir for HCV genotype 2 and 3 infection,New Eng J Med 373 2608 -17
CurryMP,O'LearyJG,BzowejN,MuirAJ,KorenblatKM,FenkelJM, 2015.Sofosbuvir and Velpatasvir for HCV in patients with decompensated cirrhosis,N Eng J Med 373 2618 -28
LangeCM,ZeuzemS. Perspectives, 2013.and challenges of interferon-free therapy for chronic hepatitis C,J Hepatol 58 583 -92
HezodeC,FontaineH,DorivalC,ZoulimF,LarreyD,CanvaV, 2014.Effectiveness of telaprevir or boceprevir in treatmentexperienced patients with HCV genotype 1 infection and cirrhosis,Gastroenterology 147 132 -42
LawitzE,SulkowskiMS,GhalibR,Rodriguez-TorresM,YounossiZM,CorregidorA, 2014.Simeprevir plus Sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: The COSMOS randomised study,Lancet 384 1756 -65
BourliereM,BenaliS,AnsaldiC,Le FolgocG,RisoA,LecomteL, 2015.Optimal therapy of genotype-2 chronic hepatitis C: What's new?,Liver Int 35 21 -26
LawitzE,PoordadF,PangPS,HylandRH,DingX,MoH, 2013.Once daily Sofosbuvir/Ledipasvir fixed dose combination with or without ribavirin resulted in ≥ 95% sustained virologic response in patients with HCV genotype 1, including patients with cirrhosis: The LONESTAR trial,Hepatology 58 315A -6A
PoordadF,HezodeC,TrinhR,KowdleyKV,ZeuzemS,AgarwalK, 2014.dasabuvir with ribavirin for hepatitis C with cirrhosis,N Engl J Med 370 1973 -82
LawitzE,PoordadF,BrainardDM,HylandRH,AnD,DvorySobolH, 2015.Sofosbuvir with peginterferon-ribavirin for 12 weeks in previously treated patients with hepatitis C genotype 2 or 3 and cirrhosis,Hepatology 61 769 -75
ZeuzemS,DusheikoGM,SalupereR,MangiaA,FlisiakR,HylandRH, 2014.Sofosbuvir and ribavirin in HCV genotypes 2 and 3,N Engl J Med 370 1993 -2001
NelsonDR,CooperJN,LalezariJP,LawitzE,PockrosPJ,GitlinN, 2015.All-oral 12-week treatment with Daclatasvir plus Sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study,Hepatology 61 1127 -35
RuanePJ,AinD,StrykerR,MeshrekeyR,SolimanM,WolfePR, 2014.Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry,J Hepatol 62 1040 -6
KapoorR,KohliA,SidharthanS,SimsZ,PetersenTL,OsinusiA, 2014.All oral treatment for genotype 4 chronic hepatitis C infection with Sofosbuvir and Ledipasvir: Interim results from the NIAID SYNERGY trial,Hepatology 60 321A -
AbergelA,Loustaud-RattiV,MetivierS., 2015.Ledipasvir/Sofosbuvir for the treatment of patients with chronic genotype 4 or 5 HCV infection. 50th Annual Meeting of the European Association for the Study of the Liver (EASL),April 22-26 -
GaneEJ,HylandRH,AnD., 2014.High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection. 65th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD),November 7-11 -
FlammSL,EversonGT,CharltonM,DenningJM,ArterburnS,Brandt-SarifT, 2014.Ledipasvir/Sofosbuvir with ribavirin for the treatment of HCV in patients with decompensated cirrhosis: Preliminary results of a prospective, multicenter study,Hepatology 60 320A -